Abstract:Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are characterized by chronic idiopathic inflammation of gastrointestinal tract. Although the pathogenesis of IBD remains unknown, intestinal immune dysfunction has been considered as the core pathogenesis. In the intestinal immune system, T helper 1 (Th1) and Th17 cells are indispensable for intestine homeostasis via preventing pathogenic bacteria invasion, regulating metabolism and functions of intestinal epithelial cells (IECs), and promoting IEC self-renewal. However, during the development of IBD, Th1 and Th17 cells acquire the pathogenicity and change from the maintainer of intestinal homeostasis to the destroyer of intestinal mucosa. Because of coexpressing interferon-γ and interleukin-17A, Th17 cells with pathogenicity are named as pathogenic Th17 cells. In disease states, Th1 cells impair IEC programs by inducing IEC apoptosis, recruiting immune cells, promoting adhesion molecules expression of IECs, and differentiating to epithelial cell adhesion molecule-specific interferon γ-positive Th1 cells. Pathogenic Th17 cells induce IEC injury by triggering IBD susceptibility genes expression of IECs and specifically killing IECs. In addition, Th1 and pathogenic Th17 cells could cooperate to induce colitis. The evidences from IBD patients and animal models demonstrate that synergistic action of Th1 and pathogenic Th17 cells occurs in the diseases development and aggravates the mucosal inflammation. In this review, we focused on Th1 and Th17 cell programs in homeostasis and intestine inflammation and specifically discussed the impact of Th1 and Th17 cell pathogenicity and their synergistic action on the onset and the development of IBD. We hoped to provide some clues for treating IBD.

The pathogenesis and immunotherapies of inflammatory bowel disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

The Immunopathogenesis and Therapies of Inflammatory Bowel Diseases

A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease

The microbiome in inflammatory bowel diseases: from pathogenesis to therapy

New Insights into Bacterial Mechanisms and Potential Intestinal Epithelial Cell Therapeutic Targets of Inflammatory Bowel Disease

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Immunopathogenesis of IBD: current state of the art

Recent Progress on the Role of Gut Microbiota in the Pathogenesis of Inflammatory Bowel Disease.

The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases

Gut microbiota in the pathogenesis of inflammatory bowel disease

New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease

New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease

Interaction Between Commensal Bacteria, Immune Response and the Intestinal Barrier in Inflammatory Bowel Disease

Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies

The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease

Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation

Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy

Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease

Microbiota as key factors in inflammatory bowel disease

Updated immunomodulatory roles of gut flora and microRNAs in inflammatory bowel diseases